Susana Cedrés

Doctor Cedrés has carried out different research works in the field of malignant pleural mesothelioma (MPM) for more than a decade. Her activity has focused on the field of research into new drugs and the search for biomarkers of response to new drugs. As part of research into new therapies, the work done at the institution has enabled patients to receive novel therapies, some of which have subsequently been approved by regulatory agencies (i.e TTFields) (Kindler H, Lancet Oncol 2022; Haakensen V, J Translational Oncol 2021; Ceresoli, Lancet Oncol 2019; Scagliotti Lancet Resp Med 2019). In the field of translational research, Dr Cedrés has carried out different biomarker studies searching for new therapeutic targets (such as PI3K and MMR deficiencies), and predictive markers of response to systemic treatments (Cedrés, Clin Trasnl Oncol 2020; Cedrés, Lung Cancer 2016). In the field of immunotherapy, the confirmation of PD-L1 expression in MPM has represented a new therapeutic possibility for these patients (Cedrés, PlosOne 2015). Morover, the analysis of histology as a predictor of efficacy to immunotherapy in MPM has contributed to better selection of patients to immunotherapy (Cedrés, Scientific Report 2021). In recent years, the activity has focused on the search for predictive biomarkers of response to immunotherapy using Next generation Sequencing (NGS) technology. In addition, the collaboration with international cooperative groups (International Association for the Study of Lung Cancer, IASLC) and the study of a large series of patients at the institution has made it possible to contribute to the development of the current proposal for TNM (Tumor Node Metastasis) staging system of the MPM (Novak, J thoracic Oncol 2016).